Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Antti Hedman"'
Autor:
Juha Hartikainen, Aleksi Johannes Leikas, Seppo Ylä-Herttuala, Iiro Hassinen, Antti Kivelä, Antti Hedman
Publikováno v:
Gene Therapy. 29:289-293
In phase I KAT301 trial, intramyocardial adenovirus-mediated vascular endothelial growth factor -DΔNΔC (AdVEGF-D) gene therapy (GT) resulted in a significant improvement in myocardial perfusion reserve and relieved symptoms in refractory angina pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::879f35dbc060d1102af67bfa3371c268
https://doi.org/10.1038/s41434-021-00295-1
https://doi.org/10.1038/s41434-021-00295-1
Autor:
Aleksi J. Leikas, Iiro Hassinen, Antti Kivelä, Antti Hedman, Hanna Mussalo, Seppo Ylä‐Herttuala, Juha E. K. Hartikainen
Publikováno v:
The Journal of Gene Medicine. 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::232e1bf9188c0e3f5b597cd7ce9c12cc
https://doi.org/10.1002/jgm.3437
https://doi.org/10.1002/jgm.3437
Autor:
Aleksi J, Leikas, Iiro, Hassinen, Antti, Kivelä, Antti, Hedman, Hanna, Mussalo, Seppo, Ylä-Herttuala, Juha E K, Hartikainen
Publikováno v:
The journal of gene medicineREFERENCES. 24(8)
The phase I KAT301 trial investigated the use of intramyocardial adenoviral vascular endothelial growth factor-DWe analyzed non-invasive risk predictors of ventricular arrhythmias from 12-lead electrocardiography (ECG) as well as heart rate variabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a298d3796ac1b7066a73564df5c242f3
https://pubmed.ncbi.nlm.nih.gov/35750637
https://pubmed.ncbi.nlm.nih.gov/35750637
Autor:
Hanna Hämäläinen, Tiina M. Laitinen, Marja Hedman, Antti Hedman, Antti Kivelä, Tomi P. Laitinen
Publikováno v:
Clinical physiology and functional imagingREFERENCES. 42(6)
In patients with coronary artery disease (CAD), ischaemic cardiomyopathy may result in progressive cardiac remodelling and left ventricular (LV) dysfunction. Myocardial perfusion imaging (MPI) can be used to quantify LV size and shape, mechanical dys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f50e24c4944fb07176c1969356a251
https://pubmed.ncbi.nlm.nih.gov/35848312
https://pubmed.ncbi.nlm.nih.gov/35848312
Publikováno v:
European Heart Journal. 42
Backgound/Introduction In phase I KAT301 trial, adenovirus-mediated intramyocardial vascular endothelial growth factor-DΔNΔC (VEGF-D) gene therapy (GT) resulted in a significant improvement in myocardial perfusion reserve and relieved angina at 1-y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::352271c3dd0208c4b6042145db5bc264
https://doi.org/10.1093/eurheartj/ehab724.3441
https://doi.org/10.1093/eurheartj/ehab724.3441
Autor:
Aleksi J, Leikas, Iiro, Hassinen, Antti, Hedman, Antti, Kivelä, Seppo, Ylä-Herttuala, Juha E K, Hartikainen
Publikováno v:
Gene therapy. 29(5)
In phase I KAT301 trial, intramyocardial adenovirus-mediated vascular endothelial growth factor -D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::37953cfb77670de46c5bb5263541b99e
https://pubmed.ncbi.nlm.nih.gov/34593990
https://pubmed.ncbi.nlm.nih.gov/34593990
Publikováno v:
European Heart Journal. 38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11007ecde66f552cb19a20a35b30ddd2
https://doi.org/10.1093/eurheartj/ehx504.p3350
https://doi.org/10.1093/eurheartj/ehx504.p3350
Autor:
Sotirios Tsimikas, Tuomas T. Rissanen, Minna Husso, Hanna Mussalo, Iiro Hassinen, Marja Hedman, Tommi Heikura, Antti Saraste, Pyry I. Toivanen, Joseph L. Witztum, Antti Hedman, Juhani Knuuti, Juha Hartikainen, Antti Kivelä, Seppo Ylä-Herttuala
Publikováno v:
European Heart Journal
Aims We evaluated for the first time the effects of angiogenic and lymphangiogenic AdVEGF-DΔNΔC gene therapy in patients with refractory angina. Methods and results Thirty patients were randomized to AdVEGF-DΔNΔC (AdVEGF-D) or placebo (control) g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03181a965178dfd005b4c843d9e4af6
https://erepo.uef.fi/handle/123456789/5793
https://erepo.uef.fi/handle/123456789/5793
Autor:
Juha Hartikainen, Esko Vanninen, Antti Hedman, Sakari Simula, Pia Pajunen, Mikko Syvänne, Seppo Lehto
Publikováno v:
Clinical Autonomic Research. 24:31-37
Heart rate variability (HRV) becomes impaired in symptomatic coronary artery disease (CAD), particularly, after myocardial infarction. The mechanism how CAD results in impairment of cardiac autonomic regulation is not known. Whether it results rather
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9162cf6ea1beea39037cd571a1bfe6f
https://doi.org/10.1007/s10286-013-0220-z
https://doi.org/10.1007/s10286-013-0220-z
Publikováno v:
Annals of Noninvasive Electrocardiology. 17:8-13
Background: Myocardial 123I-metaiodobenzylguanidine (MIBG) kinetics reflect the integrity and function of cardiac presynaptic sympathetic nerve terminals. Heart rate variability (HRV) is an indicator of cardiac sympatho-vagal balance. However, the fu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa6c92342c1b7e219a22f1fdbb4ce478
https://doi.org/10.1111/j.1542-474x.2011.00475.x
https://doi.org/10.1111/j.1542-474x.2011.00475.x